share_log

RBC Capital Maintains Outperform on Biohaven, Lowers Price Target to $58

RBC Capital Maintains Outperform on Biohaven, Lowers Price Target to $58

RBC資本維持對biohaven的跑贏大盤評級,下調目標價至58美元。
Benzinga ·  2024/11/25 12:26  · 評級/大行評級

RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Outperform and lowers the price target from $66 to $58.

RBC Capital分析師Leonid Timashev維持對biohaven(紐交所:BHVN)股票的推薦評級,並將目標價格從66美元降至58美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論